Literature DB >> 31668148

Second primary lung cancer following laryngeal cancer: retrospective study of incidence and multivariate analysis of risk factors in 209 patients.

M Adams1, G Gray1, A Kelly1, F Toner1, R Ullah1.   

Abstract

OBJECTIVE: To analyse the incidence of second primary lung cancer following treatment for laryngeal cancer and to identify risk factors for its development.
METHOD: Retrospective case series.
RESULTS: The five-year actuarial incidence of second primary lung cancer was 8 per cent (1.6 per cent per year). This was associated with a very poor median survival of seven months following diagnosis. Supraglottic tumours were associated with an increased risk of second primary lung cancer compared to glottic tumours in both univariate (hazard ratio = 4.32, p = 0.005) and multivariate analyses (hazard ratio = 4.14, p = 0.03).
CONCLUSION: Second primary lung cancer occurs at a rate of 1.6 per cent per year following a diagnosis of laryngeal cancer, and this is associated in a statistically significant manner with supraglottic primary tumour. The recent National Lung Cancer Screening Trial suggests a survival advantage of 20 per cent at five years with annual screening using low-dose computed tomography scanning of the chest in a comparable cohort to ours. These findings have the potential to inform post-treatment surveillance protocols in the future.

Entities:  

Keywords:  Early Detection Of Cancer; Laryngeal Neoplasms; Lung Neoplasms; Neoplasms, Multiple Primary; Neoplasms, Second Primary

Year:  2019        PMID: 31668148     DOI: 10.1017/S0022215119002147

Source DB:  PubMed          Journal:  J Laryngol Otol        ISSN: 0022-2151            Impact factor:   1.469


  1 in total

1.  African American race as a risk factor associated with a second primary lung cancer after initial primary head and neck cancer.

Authors:  Yusra F Shao; Seongho Kim; John D Cramer; Dina Farhat; Jeffrey Hotaling; Syed Naweed Raza; George Yoo; Ho-Sheng Lin; Harold Kim; Ammar Sukari; Misako Nagasaka
Journal:  Head Neck       Date:  2022-06-17       Impact factor: 3.821

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.